Pay in 4 interest-free payments of $21.25 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
ADX47273 dose-dependently shifted mGlu5 receptor glutamate response curve to the left (9-fold at 1 microM) and competed for binding of [(3)H]2-methyl-6-(phenylethynyl)pyridine (K(i) = 4
Water: 10 mg/mL(17
3-3 μM) dose-dependently reduces the migration of cells induced by growth factors (PDGF-BB
Multiple myeloma (MM) lines
Evidence that PERK is implicated in tumorigenesis and cancer cell survival stimulated our search for small molecule inhibitors
Tivantinib previr ADX47273 dose-dependently shifted mGlu5 receptorTivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c Met with potential antineoplastic activity. c Met inhibitor ARQ 197 binds to the c Met protein and disrupts c Met signal transduction pathways, which may induce cell death in tumor cells overexpressing c Met protein or expressing consitutively activated c Met protein. c Met protein, the product of the proto oncogene c Met, is a receptor tyrosine kinase also known as
US$ 199.00
US$ 14.99
US$ 86.99
US$ 189.50
US$ 12.99
US$ 199.50
US$ 13.99